Emergent BioSolutions, Inc. Presents at Merrill Lynch 2013 Health Care Conference, May-16-2013 10:40 AM. Venue: Encore at Wynn, 3121 Las Vegas Blvd South, Las Vegas, Nevada, United States.

Emergent BioSolutions Inc. reported unaudited consolidated financial results for the first quarter ended March 31, 2013. For the quarter, the company reported total revenues of $43.1 million as compared to $50.3 million in 2012. The year-over-year reduction was primarily a result of two factors. First, fewer BioThrax doses delivered during the period. The difference is essentially the closing of one BioThrax lot. And secondly, lower grants and contracts revenues due to payments the company received in the first quarter of 2012 from Abbott and Pfizer related to the development partnerships associated with TRU-016 and SBI-087, respectively. The company recorded a net loss attributable to company of $8.1 million, or $0.22 per basic and diluted share, as compared to a net loss of $6.83 million, or $0.19 per basic and diluted share, in 2012. Loss from operations was $13,350,000 against $12,538,000 a year ago. Loss before benefit from income taxes was $13,321,000 compared with $11,662,000 for the same period last year. Net cash used in operating activities was $4,626,000 against net cash provided by operating activities of $13,840,000 a year ago. Purchases of property, plant and equipment were $7,679,000 against $22,329,000 a year ago. For full year 2013, the company is reaffirming its forecast of total revenues of $290 to $310 million, split between product sales of $230 to $240 million and contracts and grants revenue of $60 to $70 million. The company is also reaffirming its full year 2013 net income forecast of $20 to $30 million. For the second quarter of 2013, the company anticipates total revenues of $70 to $80 million.

Emergent BioSolutions, Inc. Presents at Credit Suisse 2013 Antibody Day, May-10-2013 12:00 PM. Venue: New York, New York, United States.